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ABSTRACT
Objective: While the prevalence of type 2 diabetes is
growing, it is increasingly well recognized that
treatment outcomes in primary care practice are often
suboptimal. The aim of this study is to examine the
extent to which treatment beliefs and health behaviors
predict diabetes health outcome as measured by
glycated hemoglobin (HbA1c) level, blood pressure,
and lipid profile.
Research design and methods: This was a large-
scale cross-sectional, registry-based study involving a
well-defined type 2 diabetes population, in the county
of Funen, Denmark. Registry data were combined with
a 27-item self-reported survey administered to all
insulin-treated people in the registry (n=3160). The
survey was constructed to operationalize key concepts
of diabetes management, diabetes treatment beliefs,
and health behaviors.
Results: In total, 1033 respondents answered the
survey. The majority of treatment beliefs and health
behaviors examined were predictors of glycemic
control and, to a large extent, lipid profile. Absence
from, or a low frequency of, self-measured blood
glucose, non-adherence to general medical advice and
the prescribed treatment, a low primary care utilization,
and perceived low treatment efficacy were factors
positively associated with HbA1c levels, s-cholesterol,
and low-density lipoprotein. Conversely, infrequent
self-measured blood glucose was associated with a
significantly higher likelihood of having a blood
pressure below 130/80 mm Hg. Perceived low
treatment efficacy was the only health belief associated
with poorer levels of health outcome other than HbA1c.
Conclusions: Health behaviors were stronger
predictors for health outcomes than treatment beliefs.
Self-reported adherence to either the treatment regimen
or general medical advice most consistently predicted
both glycemic control and cardiovascular risk factors.
BACKGROUND
Diabetes imposes signiﬁcant demands on the
person with the condition for ongoing daily
self-management. Living with diabetes is
often associated with psychosocial chal-
lenges.1 2 Optimal control involves day-to-day
blood sugar monitoring, medication taking,
lifestyle adjustment, preventing and man-
aging long-term complications, coping with
the psychosocial challenges attached to living
with a chronic condition, and actively utiliz-
ing relevant diabetes support services.
Maintaining such health behaviors is a life-
long matter hampered by the fact that for
many diabetes is a silent disease. That is,
there are limited symptoms in daily life until
the day that a complication occurs. This may
be a long time after the initial diagnosis.
Thus, instant rewards of disease self-
management are limited to intermediary
treatment targets, such as blood sugar
control. The actual health beneﬁts, in terms
of mitigating cardiovascular disease (CVD)
or diabetes long-term sequela, remain a
distant event emphasizing the everyday life
diligence needed for optimal management.
The beliefs that people hold toward their
current and future health, and their level of
disease knowledge, are likely to modify the
extent to which they engage in disease self-
management. The interplay between health
beliefs, disease self-management, and health
outcome was ﬁrst delineated in the health
belief model developed by US researchers in
the 1950s.3 This model provides a conceptual
framework for understanding disparities in
why people do, or do not, engage in disease
self-management. Engaging in health-related
actions is predicted by the perceived value
Key messages
▪ Self-reported adherence to therapy was found to
be the most important patient reported predictor
of both glycated hemoglobin and cardiovascular
risk factors in people with diabetes in a large
Danish sample.
▪ Treatment adherence was associated with
improved overall life satisfaction and self-rated
health.
▪ A personalized approach to diabetes care which
considers the identified predictors of poor adher-
ence and quality of life may be helpful for
improving outcomes of type 2 diabetes manage-
ment in primary practice.
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attached to an outcome and the perceived likelihood
that these actions will lead to this outcome.4 5 Other
social cognition theories developed to predict health
behavior include self-efﬁcacy theory6 and the theory of
planned behavior.7 Treatment outcomes examined in
previous applications of these theories include adher-
ence in diabetes4 8–12 and glycemic control.13–20 Only
two studies included a composite measure of metabolic
control reﬂecting both glycemic control and cardiovas-
cular risk.21 22
The aim of this study is to examine the extent to
which different beliefs and behaviors related to diabetes
predict health outcomes. This was a large-scale cross-
sectional study involving people with type 2 diabetes in
the county of Funen, Denmark. Health outcome was in-
dicated by glycated hemoglobin (HbA1c) level, blood
pressure (BP), total serum cholesterol (s-cholesterol),
and low-density lipoprotein (LDL) cholesterol. The
health information available from the disease registry was
supplemented with self-reported demographic and psy-
chometric data from a questionnaire administered to all
insulin-treated people in the registry (n=3160).
The signiﬁcance of this study can be assessed via the
use of registry-based health data from a well-deﬁned
population of insulin users and the evaluation of dia-
betes health outcomes reﬂecting cardiovascular out-
comes and glycemic control. The results provide
direction for targeting diabetes care to patient segments
in particular need of education and self-management
support. The conceptual framework may be generalized
to a practitioner setting and is particularly relevant for
developing screening strategies in primary and second-
ary diabetes care.
RESEARCH DESIGN AND METHODS
This study was a cross-sectional registry study combined
with a postal survey of patients with type 2 diabetes in
Denmark.
Funens Diabetes Database (FDDB) is a disease registry
established in 2003 and is employed by medical out-
patient clinics, general practitioners (GP) and ophthal-
mologists in Funen. Approximately 9000 patients with
diabetes are registered in the database. Laboratory ana-
lyses are performed at local laboratories and are auto-
matically transferred to the registry. Other information is
entered manually by healthcare professionals.23
A 27-item questionnaire was developed to supplement
the health information contained in the registry. These
items were constructed to operationalize the key
concepts detailed in the research question, diabetes
treatment beliefs and health behavior. The construction
of items was based on the domains of the health belief
model3 and self-efﬁcacy theory.6 A discrete choice experi-
ment on patient preference toward the beneﬁt–risk
proﬁle of diabetes treatment formed part of the ques-
tionnaire, but this analysis is not relevant to this paper.
The generation of items was an iterative process.
Initially, one-to-one interviews were conducted with dia-
betes specialists (n=2), a diabetes nurse, a diabetes edu-
cation specialist and people with diabetes (n=3) to
identify topics and items to be included. Two focus
groups, each with four participants, were conducted to
ensure face validity, acceptability, and clarity of the ques-
tionnaire items, and logic of the overall order in which
the items were presented. All participants were insulin
users, and were recruited through a diabetes clinic at
Hilleroed Hospital, Denmark. Focus group participants
were invited to share their thoughts on the question-
naire during a 2 h session.
To enable a systematic appraisal of the questionnaire
performance, the revised questionnaire was piloted
using a small sample of intended respondents. Written
comments on the questionnaire were assessed and
changes implemented accordingly. In some cases,
response options were modiﬁed to prevent indications
of ceiling or ﬂooring effects of a particular scale.
Study population
The questionnaire was sent by postal mail to all insulin
users with type 2 diabetes in the registry (n=3160) with a
prepaid return envelope included. A unique identiﬁer
was assigned by FDDB to ensure respondent anonymity
and allow linkage between the self-reported and register
data.
Respondents were informed that by answering the
questionnaire, consent was given to obtain information
from their registered health information. No remuner-
ation was offered for participation. Access to the registry
was contingent on study approval by the Danish data
protection agency and the registry steering committee.
Diabetes registry
Health information derived from the registry is depicted
in table 1. The International Federation of Clinical
Chemistry (IFCC) HbA1C values were converted to the
Diabetes Control and Complication Trial (DCCT) stand-
ard values using the following formula: (0.09148*IFCC)
+2.152.24
The Danish treatment guidelines for type 2 diabetes
were used to deﬁne health outcome. For patients with
type 2 diabetes without CVD, these are HbA1c<6.5%
(<47.5 mmol/mol), s-cholesterol <4.5 mmol/L, LDL-
cholesterol <2.5 mmol/L, and BP<130/80 mm Hg. For
patients with or at high risk of CVD, the recommenda-
tions are HbA1c<7.5% (<58.5 mmol/mol), s-cholesterol
<4.0 mmol/L, and LDL-cholesterol <2 mmol/L
(BP<125/75 mm Hg in renal disease).25
To evaluate the CVD risk of the sample population, a
type 2 diabetes-speciﬁc equation for estimation of 5-year
ﬁrst incident fatal/non-fatal CVD was calculated using
the formula, 5-year risk (CVD)26=(1−exp [−(q5
×β1age-duration×β2sex×β3duration×β4HbA1c×β5BMI×β6antihypertens-
ive drugs×β7systolic blood pressure×β8lipid lowering drugs×β9smoker)])
×100.
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Table 1 Domains in the survey instrument and diabetes registry
Domain Survey instrument Scale Diabetes registry
Sociodemographic Education
Occupation
Household and own income
Health insurance
7 Categories
7 Categories
1 (Below 149K DKK)
to 7 (>850K DKK)
Yes/no
Age
Sex
Weight (kg)/height (cm)
BMI
Duration of diabetes
(years)
Health status
Measurements Self-measured BG (mmol/L) after questionnaire
completion
<5 to >18 mmol/L HbA1c (%)
LDL (mmol/L)
HDL (mmol/L
S-cholesterol (mmol/L)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Mental/physical
health
Limitation during physical activity (self-rated NYHA
class I-IV)
Well-being and mobility
Life satisfaction
Multiple choice
(4 health states)
EQ-5D
1 (very dissatisfied)
to 10 (very satisfied)
Severe
complications
Severe hypoglycemia
Night-time hypoglycemia
(total number)
(yes/no)
Severe hypoglycemia
(total number)
Ketoacidosis
(total number)
Retinopathy
Foot risk
Foot ulcer
Amputation
Kidney failure (yes/no)
Apoplexy (total
number)
Vascular operation
(total number)
Angina (yes/no)
Heart failure (yes/no)
Minor
complications
Minor hypoglycemic events (per month) –
Treatment regimen – – Insulin regimen
Antihypertensive
treatment
Antilipidemic treatment
Health behavior
Daily habits Exercise (intensity/frequency)
Smoker
Home measured BG
1 (high) to 4 (low)
Yes/no
(number per week)
–
Self-efficacy Own ability to engage in health promoting actions:
(1) diet, (2) exercise, (3) dentist visits, (4) GP
advice adherence (5) visiting one’s GP (primary
care utilization), (6) treatment adherence
1 (Poor) to 10
(very good)
–
Treatment
adherence
Level of treatment adherence 1 (not at all) to 4
(fully)
–
Health beliefs
Susceptibility to
health risk
Familiarity with HbA1c
Understanding of HbA1c and its association with BG
in the past 3 months
Satisfactory HbA1c level
Perception of own heart health/condition
Yes/no/do not know
Multiple choice
(3 statements)
HbA1c 5.5–10%
1 (poorest) to 10
(best possible)
–
–
–
–
Continued
BMJ Open Diabetes Research and Care 2016;4:e000166. doi:10.1136/bmjdrc-2015-000166 3
Clinical care/education/nutrition/psychosocial research
group.bmj.com on April 7, 2017 - Published by http://drc.bmj.com/Downloaded from 
Self-reported questionnaire data
Health behavior was evaluated through questions on
dietary habits, smoking, exercise, treatment adherence,
self-measured blood glucose (SMBG) testing, and
respondent primary care utilization. The scale used for
these questions was ordinal (eg, Q: ‘To what extent do
you comply with your diabetes treatment?’ A: ‘not at all,
to some extent, to a high extent, fully’). Others were
presented as a scale from 1 to 10 (1=very poor and
10=very good), for example, ‘How good/poor are you at
doing what you know is best for you?’. Respondents then
had to answer this for 6 different behaviors related to
diet, exercise, keeping to dentist/GP visits, taking one’s
medication, and adhering to medical advice.
Treatment beliefs were assessed through questions
examining respondents’ attitudes toward treatment and
understanding of diabetes. Treatment attitudes were
stated on an ordinal scale (very much disagree to very
much agree), for example, ‘The treatment doesn’t
improve my diabetes much’. The respondent’s under-
standing of HbA1c was revealed with a set of questions
on whether the respondents (1) had heard of HbA1c
before (yes/no), (2) could identify the correct answer
out of three on the interpretation of HbA1c as a long-
term marker of blood glucose control (multiple choice),
and (3) could state their HbA1c target within a range of
values between 5.5% and 10% (multiple choice).
Respondent understanding of long-term sequela was
revealed by a multiple choice question (yes/no/do not
know) asking the respondents to mark the places where
one is at risk of damage due to prolonged high blood
sugar (hands, feet, heart, kidneys, eyes, teeth/gums).
The classiﬁcation of level of education and occupation
were guided by standards commonly used in
Denmark.27 28 All questionnaire domains are mapped
against the registry data in table 1.
Statistical analysis
SAS for Windows V.9.3 (SAS Institute Inc, Cary, North
Carolina, USA) was used for data management and stat-
istical analysis. Relevant variables were categorized, and
descriptive statistics were shown as a number and
percentage for each variable level. The Danish
EuroQOL ﬁve dimensions questionnaire (EQ-5D) valu-
ation algorithm29 was used to calculate a single index
score for all ﬁve EQ-5D dimensions.
Forward stepwise multiple regressions were per-
formed, regressing a dependent variable on a set of
potential explanatory variables in a one-by-one manner.
The explanatory variables included in these analyses
were: age, gender, body mass index (BMI), duration of
diabetes, insulin regimen, smoking status, education,
income, self-reported New York Heart Association
(NYHA) class, physical activity level, EQ-5D score, and
life satisfaction. The health outcomes regressed were:
HbA1c, s-cholesterol, LDL, and systolic BP.
Subsequently, the variable most strongly associated
with a dependent variable was identiﬁed and included
in models against each of the dependent variables. The
variables explaining the largest amount of the remaining
variation was kept in the models.
Normal plots of residuals from the regression models
were made, and the data log-transformed if needed. For
descriptive purposes, the arithmetic mean and CIs calcu-
lated from log-transformed data were adjusted back to
their original scale through exponentiation.30
Logistic regression analyses were used to estimate odds
ratios (ORs) for meeting diabetes treatment goals in the
presence of prespeciﬁed diabetes management beha-
viors or treatment beliefs. These were included in logis-
tic regression analyses if signiﬁcant at the 0.15 level for
more than one of the health outcomes in the individual
regression analyses. This level of signiﬁcance was
selected to ensure that all relevant behaviors and beliefs
were tested in logistic regression models.
The aim of the analyses was to examine the association
between health outcome (HbA1c, s-cholesterol, LDL,
and BP), treatment beliefs, and health behavior. To
support these ﬁndings, subanalyses on predictors of
beliefs and behavior were performed. Behaviors and
beliefs signiﬁcantly associated with meeting more than
one treatment target were regressed individually on rele-
vant explanatory factors in backward stepwise logistic
regression. The background data selected for these
Table 1 Continued
Domain Survey instrument Scale Diabetes registry
Severity of
diabetes
Specifying where damage may occur due to poor
glucose control (hands, feet, heart, kidneys, eyes,
teeth/gums)
Yes/no/do not know –
Barriers toward
treatment
(1) finding the treatment cumbersome, (2)
time-consuming or (3) skipping treatments due to
financial burden
1 (disagree) to 5
(very much agree)
–
Benefits of
treatment
(1) finding it does not improve one’s condition much
and (2) feeling well despite not always following the
treatment
1 (disagree) to 5
(very much agree)
–
BG, blood glucose; BMI, body mass index; BP, blood pressure; DKK, Danish Krone; EQ-5D, EuroQOL five dimensions questionnaire; GP,
general practitioner; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart
Association.
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analyses were age, gender, BMI, smoking status, insulin
regimen, duration of diabetes, self-reported NYHA class
and heart health, EQ-5D score and life satisfaction,
minor and major hypoglycemic events, income and
education.
RESULTS
Of the 3160 distributed questionnaires, one-third
(1031/33.3%) were returned. Age was the only variable
available on non-responders, but did not differ signiﬁ-
cantly from the respondent group (66±SD 13 vs 67±SD
11).
The average respondent was male, 67 years of age,
diagnosed with diabetes for 15 years and with HbA1c,
LDL, and cholesterol levels slightly above recommenda-
tions. More than half had high BP. The combination of
long-term diabetes, elevated HbA1c and cholesterol
levels, being overweight, and hypertension induced an
average 5-year cardiovascular event risk of 27%. Since
most respondents were elderly and at risk of CVD, the
treatment target recommended for this population was
applied in all logistic regression analyses.
Approximately two-thirds of the respondents were
outside the labor market. The majority (69%) were of a
low education level (highest degree high school or tech-
nical college) with a household income of <250 000
Danish Kroner (DKK) (75%). Intermediary diabetes
damage (eyes or feet) affected up to 46% of the respon-
dents. Terminal damage (amputation or renal failure)
affected 5% of the respondents (table 2).
Log-transformations were made for all health out-
comes, except systolic BP. Covariates signiﬁcantly asso-
ciated with any treatment outcome at the 0.05 level in
linear and logistic regression analyses were: duration of
diabetes, insulin regimen, smoking, age, self-reported
NYHA class, gender, and age. Results for linear regres-
sion analyses in which each health outcome (HbA1c, sys-
tolic BP, s-cholesterol, and LDL) was regressed on health
behaviors and treatment beliefs are shown in tables 3
and 4.
Diabetes treatment beliefs
More than half of the respondents were satisﬁed with an
HbA1c level below 7.5%. The majority of respondents
had heard of HbA1c previously. A minority of 4%
thought that the HbA1c measurement correlated with
the self-measured morning blood glucose measured the
same day. One-third did not associate heart disease with
diabetes management. Neuropathy and its related
damage to feet was known by most respondents (91.7%)
but not damage to hands (24.5%) (table 5).
Approximately one-third (34%) found their treatment
cumbersome and 22% stated that it did not improve
their diabetes much (perceived low treatment efﬁcacy)
or found the treatment very time-consuming. A small
number of respondents (12%) could not reject budget
constraints as a reason for sometimes skipping
treatment. Higher HbA1c levels were associated with per-
ceived low treatment efﬁcacy and the belief that an
HbA1c level above 7.5 was satisfactory. The treatment
beliefs included in linear regression analyses are shown
in table 3.
Table 2 Demography and health (n=1033)
Age, mean (SD) 67.1 (10.4)
Male sex, n (%) 636 (61.6)
BMI, mean (SD) 31.8 (6.3)
EQ-5D, mean (SD) 0.8 (0.2)
HbA1c (%), mean (SD) 7.6 (1.3)
HbA1c mmol/mol, mean (SD) 59.7 (13.9)
LDL mmol/L, mean (SD) 2.1 (0.8)
S-cholesterol mmol/L, mean (SD) 4.1 (1.0)
Diabetes duration, years, mean (SD) 15.6 (7.6)
5-year CVD event risk, mean (SD) 26.7 (15.4)
High BP (>130/80 mm Hg), n (%) 594 (58.1)
Smoker, n (%) 160 (16.0)
Hypoglycemic events, n (%)
Non-severe, the past week
None 352 (45.2)
1–5 377 (48.5)
>6 33 (4.3)
Severe, in a lifetime, n (%)
None 61 (78.9)
1 81 (10.4)
>1 73 (9.4)
Self-measured blood glucose, per week, n (%)
None/do not know 174 (21.8)
1–6 317 (39.8)
7 or more 183 (23.0)
Complications, n (%)
Foot wound 58 (5.8)
Amputation (foot/leg) 19 (1.9)
Retinopathy, mild 353 (35.2)
Retinopathy, severe 50 (5.0)
Renal failure 43 (4.6)
Heart failure, n (%) 36 (4.5)
Vascular surgery, n (%) 65 (6.7)
Education, n (%)
Primary school/high school 361 (39.0)
Technical college 289 (31.1)
Medium length (≤4 years) 233 (25.1)
Higher education (≥5 years) 45 (4.9)
Income (DKK), n (%)
Up to 149 000 372 (39.6)
150 000–249 000 324 (34.5)
250 000–374 000 139 (14.8)
375 000 and above 104 (11.1)
Labor market attachment, n (%)
None 798 (79.6)
Other (undefined) 40 (4.0)
Unskilled worker 33 (3.3)
Skilled worker 34 (3.4)
Self-employed 41 (4.1)
Official/white-collar worker 57 (5.7)
BMI, body mass index; BP, Blood Pressure; CVD, cardiovascular
disease; DKK, Danish Krone; EQ-5D, EuroQOL five dimensions
questionnaire; HbA1c, glycated hemoglobin; LDL, low-density
lipoprotein.
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Perceived low treatment efﬁcacy was the only health
belief associated with other treatment outcomes than
HbA1c. Thus, people who did not reject the statement
‘The treatment doesn’t better my diabetes much’
were 30% and 40% less likely to have s-cholesterol
<4 mmol/L (OR 0.7, CI 0.5 to 1.0) or HbA1c<7.5%
(58.5 mmol/mol) (OR 0.6, CI 0.5 to 0.9).
Health behaviors
With the exception of eating habits and exercise, the
majority of respondents stated a high self-efﬁcacy within
the domains of primary care utilization and adherence.
To the question ‘How good are you at doing what you
know is best for you?’, the distribution of answers of
eight or more (on a scale of 1 (poor) to 10 (very
good)) was: visiting my dentist (71%), visiting my GP
(82%), following my GP’s advice (89%), and taking my
medication (95%). In a multiple choice questionnaire
item, 78% stated that they were either fully or to a large
extent adhering to their treatment. More than half of
the respondents measured their blood glucose at home
at least once a week (table 2).
The majority were non-smokers (table 2), and more
than half of the sample (628; 63.2%) was moderately
active at least 4 h/week. A minority reported intense
exercise of 4 h/week (27; 2.7%) and one-third (339;
34.1) were sedentary. Approximately two-thirds exercised
at least 4 h/week (table 1). All health behaviors, apart
from being a smoker, were signiﬁcantly associated with
lower mean HbA1c levels. Frequency of SMBG, adher-
ence to general medical advice or the treatment itself,
and primary care utilization were signiﬁcantly associated
with both HbA1c and lipid proﬁle in linear regression
analyses (table 4).
Respondents stating a low adherence with either
general medical advice or their treatment regimen were
40–60% less likely to meet their HbA1c goal (OR 0.4, CI
0.3 to 0.6 and OR 0.6, CI 0.4 to 0.8) of 7.5%
(58.5 mmol/mol) and 30% less likely to meet their LDL
goal (OR 0.7, CI 0.5 to 1.0 and OR 0.7, CI 0.5 to 1.0) of
2 mmol/L.
Infrequent SMBG decreased the likelihood of meeting
an HbA1c target (OR 0.6, CI 0.4 to 1.9) of 7.5%
(58.5 mmol/mol), s-cholesterol (OR 0.7, CI 0.4 to 1.0)
of 4 mmol/L, and LDL recommendations (OR 0.6, CI
0.4 to 1.0) of 2 mmol/L or below, but conversely
induced an 80% higher likelihood of having a BP (OR
1.8, CI 1.1 to 3.0) below 130/80 mm Hg.
Low self-reported primary care utilization was signiﬁ-
cantly associated with having an HbA1c below 7.5%,
58.5 mmol/mol (OR 0.8, CI 0.6 to 1.0) but no other
health outcome.
Predictors of treatment belief and health behavior
Adherence to either the treatment regimen or general
medical advice, as well as SMBG, was signiﬁcantly asso-
ciated with a higher likelihood of meeting the treatment
target for both HbA1c and BP and lipid proﬁle. Thus,
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Table 4 Health outcome stratified by diabetes health behavior
Mean (CI) HbA1c, % and mmol/mol p Value N Systolic BP, mm Hg p Value N
s-Cholesterol,
mmol/L p Value N LDL, mmol/L p Value N
Weekly self-measured blood glucose
None/do not
know
7.9 (6.5 to 9.6); 63 (48 to 81) 0.018 107 130.1 (100.2 to 161.5) 0.559 72 4.2 (3.4 to 5.3) 0.124 110 2.0 (1.5 to 2.8) 0.224 109
1–7 times a
week
7.4 (6.4 to 8.7); 57 (46 to 72) 382 132.3 (115.2 to 149.7) 260 4.0 (3.2 to 5.0) 383 1.9 (1.2 to 2.8) 382
1–3 times a day
or more
7.5 (6.5 to 8.6); 58 (48 to 70) 405 132.4 (116.9 to 148.2) 324 4.0 (3.2 to 5.0) 419 1.9 (1.3 to 2.8) 416
Treatment adherence
Low/moderate 7.9 (6.7 to 9.5); 63 (50 to 80) <0.001 186 132.4 (129.9 to 135.0) 0.783 123 4.1 (3.2 to 5.3) 0.114 189 2.0 (1.4 to 2.9) 0.120 184
Average/high 7.4 (6.4 to 8.6); 57 (46 to 70) 705 132.2 (131.1 to 133.5) 518 4.0 (3.2 to 5.0) 730 1.9 (1.3 to 2.8) 711
Medical advice adherence
Low/moderate 8.0 (6.8 to 9.4); 64 (51 to 79) <0.001 226 132.0 (110.6 to 153.4) 0.587 162 4.1 (3.3 to 5.2) 0.040 233 2.0 (1.4 to 2.9) 0.017 223
Average/high 7.4 (6.4 to 8.6); 57 (46 to 70) 653 132.3 (119.4 to 145.2) 469 4.0 (3.2 to 5.0) 672 1.9 (1.3 to 2.8) 658
Smoker
Yes 7.5 (6.4 to 8.7); 58 (46 to 72) 0.433 761 130.5 (120.7 to 144.5) 0.359 102 4.0 (3.2 to 5.1) 0.890 134 1.9 (1.3 to 2.8) 0.278 132
No 7.7 (6.4 to 9.2); 61 (46 to 77) 139 132.5 (103.2 to 158.5) 529 4.0 (3.2 to 5.0) 772 2.0 (1.4 to 2.8) 749
Primary care utilization
Low/moderate 7.7 (6.6 to 9.0); 61 (49 to 75) 0.028 323 132.2 (115.2 to 149.6) 0.414 168 4.1 (3.2 to 5.2) 0.250 230 2.0 (1.3 to 2.9) 0.133 229
Average/high 7.4 (6.4 to 8.7); 57 (46 to 72) 553 132.0 (117.6 to 146.3) 472 4.0 (3.2 to 5.0) 664 1.9 (1.3 to 2.7) 660
Maintaining healthy eating habits
Low/moderate 7.8 (6.7 to 9.2); 62 (50 to 77) 0.002 135 131.4 (102.3 to 160.6) 0.867 90 4.1 (3.3 to 5.1) 0.298 136 2.0 (1.4 to 2.7) 0.561 132
Average/high 7.5 (6.4 to 8.7); 58 (46 to 72) 746 132.3 (120.7 to 144.2) 532 4.0 (3.2 to 5.0) 758 1.9 (1.3 to 2.8) 738
Exercise
Low/moderate 7.7 (6.5 to 9.1); 61 (48 to 76) 0.008 332 132.4 (111.2 to 153.8) 0.824 234 4.0 (3.2 to 5.1) 0.729 336 1.9 (1.3 to 2.8) 0.307 326
Average/high 7.4 (6.4 to 8.6); 57 (46 to 70) 554 132.1 (119.8 to 144.5) 390 4.0 (3.2 to 5.0) 563 1.9 (1.3 to 2.8) 549
Estimates from analysis of covariance adjusted for (1) insulin regimen, smoking, age, duration of diabetes, (2) age and self-reported NYHA class, (3) age and gender, and (4) insulin regimen
and gender. Geometric means are shown for log-transformed data (HbA1c, s-cholesterol and LDL).
BP, blood pressure; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; NYHA, New York Heart Association.
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these behaviors were regressed individually on relevant
explanatory factors as described in the methods section.
Respondents stating adherence to general medical
advice were more likely to be women (OR 1.7, CI 1.2 to
2.4), whereas stating a low or medium life satisfaction
was associated with a 60% reduction in likelihood of
adhering to general medical advice (OR 0.4, CI 0.2 to
0.6 and OR 0.4, CI 0.3 to 0.6) or the treatment regimen
(OR 0.5, CI 0.3 to 0.8 and OR 0.7, CI 0.5 to 1.0).
Furthermore, respondents stating a low adherence to
their treatment regimen were 50% more likely to report
poorer heart health (OR 0.5, CI 0.3 to 0.9) and were
40% more likely to have a low knowledge about the con-
sequences of poor control in terms of long-term sequela
(OR 0.6, CI 0.4 to 1.0).
Respondents measuring their blood glucose weekly or
more often were twice as likely to have experienced at
least one minor hypoglycemic event within the past
month (OR 2.0, CI 1.2 to 3.3).
DISCUSSION
In this cross-sectional study, the associations between
treatment beliefs, health behavior, and health outcomes
targeting both glycemic control and CVD risk were
examined. The average respondent was male, elderly,
not attached to the labor market, with an education of
<3 years (Academy Profession degree level), and with
diabetes for 10 years or more. The demography of the
study population is highly representative of the Danish
background population of insulin users with type 2 dia-
betes. More Danish men with type 2 diabetes (up to
60%) than women are using insulin.31–33 In a Danish
cross-sectional study (n=9951), 70% of the insulin users
were outside the labor market, mainly due to retire-
ment.33 In our study, this number was 79.6%. Since age
does not differ between responders and non-responders,
non-retired, labor market attached insulin users seem
slightly under-represented in the study population. Of
the general population with diabetes (both insulin and
non-insulin users) in the region of Copenhagen
(n=47 100), 85% have an education of 4 years or less
and 42% have an income below 150 000 DKK, corre-
sponding to 95.2% and 39.6%, respectively, in our
study.34 We note that insulin users only, and none with
type 1 diabetes, were included, which may explain the
10% difference in people with an education of 4 years
or less between our study and the general diabetes
population.
It was assumed that the sample population would be
elderly and have a long average duration of diabetes.
Although most surveys involving discrete choice experi-
ments are web enabled,35 postal survey distribution was
chosen to reach a group of respondents who may reject
digital surveys. This assumption was guided by the high
number of elderly citizens obtaining waivers to a recent
mandatory requirement of using digital communication
with the Danish public sector.36 The resulting response
rate is within the expected range for the population.37 38
Health behaviors most consistently predicted health
outcome. For HbA1c, smoking was the only behavior not
associated with any change in glycemic control.
Self-reported adherence, either to treatment or general
medical advice, was associated with HbA1c and lipid
proﬁle. The use of self-reported adherence questions of
the kind applied in our study has been shown to gener-
ate valid results when compared to objective
measures.39 40
A contradictory result was that while frequent home
blood glucose measurement improved glycemic control
and lipid proﬁle, it was also associated with a higher risk
of high BP.
In general, the respondents had a high HbA1c under-
standing. In a US study (n=1233), 82% of the respon-
dents with either type 1 or type 2 diabetes had heard of
HbA1c previously.
14 In a similar study in the UK,41
two-thirds of type 2 diabetes insulin users were unfamil-
iar with HbA1c. Only 13% of these could correctly inter-
pret HbA1c in terms of its association with blood glucose
during the preceding 3 months versus 56% in the
present study. We used the exact same measure for tech-
nical HbA1c understanding but, unlike these authors,
did not establish an association with either educational
level or income.41 Respondent’s self-stated target HbA1c
was highly predictive of actual HbA1c, but we did not
Table 5 Respondent understanding of HbA1c and
diabetes long-term complications
N (%)
Satisfactory HbA1c level
<6.5% (48 mmol/mol) 164 (16.6)
6.5–7.4% (48–57 mmol/mol) 447 (45.2)
7.5–8.4% (58–68 mmol/mol) 206 (20.8)
8.5% or more (69 mmol/mol or more) 74 (7.5)
Do not know 99 (10.0)
HbA1c familiarity
Yes, I have heard of the glucose test
(HbA1c) before
894 (90.0)
No, I have not heard of the glucose test
(HbA1c) before
61 (6.1)
Do not know 39 (4.0)
Technical HbA1c understanding
A HbA1c of 9%…
Means that my morning blood sugar was
also 9 mmol/L
50 (5.6)
Says something about how my blood
sugar has been in the past 3 months
496 (56.2)
Means that my blood sugar on average
has been 9 mmol/L in the past 3 months
336 (38.1)
Places at risk of damage due to high blood sugar
Hands 206 (24.5)
Feet 878 (91.7)
Heart 590 (66.0)
Kidneys 755 (81.1)
Eyes 906 (93.6)
Teeth/gums 383 (44.4)
HbA1c, glycated hemoglobin.
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measure if respondents knew their HbA1c levels. Others
doing so, did not ﬁnd that knowledge of one’s
HbA1c level translated into improved diabetes
self-management.42
This study is in line with other research applying
social cognition theory to identify barriers to treatment
and explore individual psychosocial and behavioral
modiﬁers of health outcomes. We found that patients
who experience the treatment as cumbersome have
lower treatment adherence and higher HbA1c levels.
This is in line with other studies showing a high burden
on people with diabetes related to interference of dia-
betes medications in daily life1 and links between this
burden and skipping insulin injections.43 Also, respon-
dents stating themselves as satisﬁed with moderate gly-
cemic control (or did not know which level they were
satisﬁed with) tended to have actual HbA1c measure-
ments reﬂecting these statements.
While most treatment beliefs and health behaviors
were associated with HbA1c, only a few predicted meta-
bolic control associated with both glycemic and CVD
risk targets. Since people with diabetes are at a high risk
of CVD, these results indicate that attention in diabetes
care is needed to improve CVD risk.
These ﬁndings highlight potential opportunities for
improving care and support for people with diabetes.
First, they highlight simple self-reported indicators of
poor adherence which may be useful for the care team
as part of ongoing diabetes care to identify individuals
in need of additional self-management support. These
are tools often lacking in primary care.44 45
Second, our ﬁnding that patient understanding of
health consequences of poor glycemic control was more
strongly associated with adherence than a technical
understanding of HbA1c suggests that diabetes educa-
tion, which is focused on the direct relevance of
markers for the patients’ health, may be most effective.
This study was not without limitations. The study data
represented one-third of the full population invited to
take part in the survey. However, further research is
needed to evaluate characteristics of the non-
responders. Owing to the cross-sectional design of the
study, causal relationships cannot be examined, nor tem-
porality of effects. Since associations between a snapshot
of health beliefs and behaviors and registry-based health
outcomes measured at various points in time were evalu-
ated, bias was mitigated by only including health out-
comes obtained <1 year prior to survey completion.
The generalizability of the results include (1) the par-
ticular demographics, and (2) the healthcare setting of
the study population. The study population was elderly
and many were retired, which limited the analysis of
socioeconomic factors, such as income and labor market
attachment. This is a general challenge in the popula-
tion of insulin users, although others have reported an
association between socioeconomic status and adher-
ence in diabetes management.42 This tendency was
observed, but further examination was limited by the
small sample of individuals available for the analysis.
Furthermore, the diabetes model on Funen is well estab-
lished with a high level of supportive diabetes services
and education made available. Thus, the treatment
beliefs observed in the study population may not be rep-
resentative of other health systems.
CONCLUSION
Health behaviors were stronger predictors of health
outcome than treatment beliefs. Self-reported adher-
ence to either the treatment regimen or general
medical advice most consistently predicted metabolic
control of glycemic levels and cardiovascular risk factors.
These ﬁndings are based on associations only, but never-
theless detail predictive behaviors which could be tar-
geted for improvement with the hope of better health
outcomes.
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